Business:
Cancer Immunotherapies
Drug notes:
XTX202 Clin1 solid tumors; XTX301 Clin1 solid tumors
About:
Xilio Therapeutics is developing immunotherapies to improve cancer patient outcomes. Immunotherapy is the latest successful frontier in cancer treatment. Xilio is using their proprietary geographically precise solutions (GPS) platform to engineer novel molecules, including cytokines, to optimize therapeutics. The GPS platform designs molecules that only get activated in the tumor microenvironment, thus enhancing the molecules’ anti-tumor activity and localizing this potent activity. This has the benefit of reducing side effects seen in systemic therapies. Xilio is developing a range of molecules, with promising preclinical data for their lead candidates that show the potential of the system to create tumor-selective therapeutics. Xilio is also hoping to apply the GPS platform to inflammatory diseases.
Associate Scientist, Immunology Waltham, MA|30 days ago
Associate Scientist/Scientist, Biophysical Charact... Waltham, MA|30 days ago
Scientist, Cell Pharmacology Waltham, MA|30 days ago
Scientist, In Vivo Pharmacology Waltham, MA|30 days ago
Director, Program Management Waltham, MA|99 days ago
Associate Director, Clinical Science Waltham, MA|100+ days ago